XML 106 R86.htm IDEA: XBRL DOCUMENT v3.20.4
Quarterly Financial Information (Unaudited) (Details) - USD ($)
 3 Months Ended 12 Months Ended
Dec. 31, 2020
Sep. 30, 2020
Jun. 30, 2020
Mar. 31, 2020
Dec. 31, 2019
Sep. 30, 2019
Jun. 30, 2019
Mar. 31, 2019
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Disaggregation of Revenue [Line Items]                      
Total revenues $ 5,580,581 $ 236,178 $ 267,187 $ 1,327,274 $ 279,488 $ 866,863 $ 135,673 $ 2,829,905 $ 7,411,220 $ 4,111,930 $ 30,481,897
Research and development 26,302,561 26,455,112 22,376,575 19,111,188 22,003,955 19,137,209 22,486,266 24,389,888 94,245,436 88,017,319 95,257,876
General and administrative 8,617,458 10,110,506 11,071,510 7,448,354 8,696,586 5,681,441 5,850,101 6,975,029 37,247,828 27,203,156 29,315,159
Total operating expenses 34,920,019 36,565,618 33,448,085 26,559,542 30,700,541 24,818,650 28,336,367 31,364,917 131,493,264 115,220,475 124,573,035
Loss from operations (29,339,438) (36,329,440) (33,180,898) (25,232,268) (30,421,053) (23,951,787) (28,200,694) (28,535,012) (124,082,044) (111,108,545) (94,091,138)
Interest income 931,168 896,710 1,067,399 416,569 587,679 637,438 755,330 625,535 3,311,846 2,605,981 2,264,747
Interest expense (1,068,008) (1,984,046) (2,846,641) (2,803,755) (2,668,837) (2,428,671) (2,194,783) (656,248) (8,702,450) (7,948,539) 0
Change in fair value of derivative liability 0 35,306,000 (97,755,000) (13,221,977) (4,315,105) 2,551,453 0 0 (75,670,977) (1,763,652) 0
Gain (loss) on investment in affiliated entities 306,317 26,951,898 (3,883,176) 13,181,619 (1,681,401) (485,841) (173,212) (750,103) 36,556,658 (3,090,557) (1,988,567)
Net unrealized gain on available-for-sale equity securities 1,070,975 1,315,980 4,358,634 (5,050,092)         1,695,497 0 0
Other income (expense), net 9,350 (136,644) (152,102) (425,500) 263,571 140,956 127,512 (35,839) (704,896) 496,200 (1,343,856)
Gain on deconsolidation of Geneos 0 0 4,121,075 0         4,121,075 0 0
Net loss before income tax benefit/(provision for income tax) (22,415,201) 20,931,010 (128,270,709) (33,135,404) (38,235,146) (23,536,452) (29,685,847) (29,351,667) (162,890,304) (120,809,112) (94,798,019)
Income tax benefit         87,764 0 106,771 62,800 0 257,335 (2,169,811)
Share in net loss of Geneos (1,923,179) (1,759,674) (901,757) 0         (4,584,610) 0 0
Net loss (24,338,380) 19,171,336 (129,172,466) (33,135,404) (38,147,382) (23,536,452) (29,579,076) (29,288,867) (167,474,914) (120,551,777) (96,967,830)
Net loss attributable to non-controlling interest 0 0 469,407 594,350 485,344 445,759 191,850 69,605 1,063,757 1,192,558 0
Net loss attributable to Inovio Pharmaceuticals, Inc. $ (24,338,380) $ 19,171,336 $ (128,703,059) $ (32,541,054) $ (37,662,038) $ (23,090,693) $ (29,387,226) $ (29,219,262) (166,411,157) (119,359,219) (96,967,830)
Net income (loss) per share                      
Basic (in USD per share) $ (0.14) $ 0.12 $ (0.83) $ (0.26) $ (0.38) $ (0.23) $ (0.30) $ (0.30)      
Diluted (in USD per share) $ (0.14) $ 0.11 $ (0.83) $ (0.26) $ (0.38) $ (0.25) $ (0.30) $ (0.30)      
Convertible Bonds                      
Disaggregation of Revenue [Line Items]                      
Gain (loss) on extinguishment of debt $ 0 $ (8,177,043) $ 0 $ 0         (8,177,043) 0 0
6.50% Convertible Senior Notes Due 2024                      
Disaggregation of Revenue [Line Items]                      
Gain (loss) on extinguishment of debt 5,674,435 3,087,595 0 0         8,762,030 0 0
Revenue under collaborative research and development arrangements                      
Disaggregation of Revenue [Line Items]                      
Total revenues 5,003,494 21,490 74,102 71,500 $ 184,523 $ 617,427 $ 64,283 $ 2,770,712 5,170,586 3,636,945 29,860,785
Revenue under collaborative research and development arrangements from affiliated entities                      
Disaggregation of Revenue [Line Items]                      
Total revenues 82,774 103,684 95,146 1,172,126 55,665 53,014 71,390 55,579 1,453,730 235,649 449,524
Other revenue, including from affiliated entities                      
Disaggregation of Revenue [Line Items]                      
Total revenues $ 494,313 $ 111,004 $ 97,939 $ 83,648 $ 39,300 $ 196,422 $ 0 $ 3,614 $ 0 $ 1,800 $ 0